So does the news advance the optimism or is it simply a rehash of what we knew from a day ago?
ASX/Media Announcement
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data
Expected in Late 2020
• Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus
placebo at the 6-month landmark
• Increased Overall Response Rate (ORR) of 48.3% in the efti group versus 38.4% in the placebo group
• Immutep will advance discussions with regulatory authorities regarding the next clinical development
steps for efti
• Global webcast at 8am AEDT on Thursday March 26th / 5pm US EDT on Wednesday March 25th,
webcast details below
SYDNEY, AUSTRALIA – March 25, 2020 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer
and autoimmune diseases, announces data from its Phase IIb AIPAC clinical trial in HER2-negative / Hormone
Receptor positive (HR+) metastatic breast cancer (MBC).
AIPAC is a multicentre, placebo-controlled, double-blind, randomised study evaluating the Company’s lead
product candidate, eftilagimod alpha (efti, LAG-3Ig or IMP321) in combination with paclitaxel, a taxane
standard of care chemotherapy, in 227 MBC patients to boost the T-cell immune responses against tumours.
63% of patients who received paclitaxel plus efti were progression-free at the 6-month landmark (at the end
of the chemo-immunotherapy combination phase) and according to RECIST 1.1 based on blinded independent
central readers (BICR). This compares favourably to 54% of patients who received paclitaxel plus placebo. The
PFS data yielded an unadjusted hazard ratio (HR) of 0.93. The secondary endpoint of Overall Response Rate
(ORR) increased to 48.3% in the efti group, from 38.4% in the placebo group.
Favourable results were reported in multiple predefined patient subgroups, e.g.:
A) patients with low monocytes count at baseline had a positive HR of 0.61 (median PFS of 5.45 vs. 7.29
months) favouring efti
B) patients with a more aggressive, more immunogenic luminal B type had a positive HR of 0.65 (median
PFS of 5.45 vs. 7.29 months) favouring efti
C) patients with lower general performance status at baseline had a positive HR of 0.76 (median PFS of
6.67 vs. 7.13 months) favouring efti
The combination of efti and paclitaxel chemotherapy was overall safe and well tolerated, further building
upon efti’s strong safety profile to date. I
These results, together with consideration of the Overall Survival (OS) and the immuno-monitoring data
expected to be reported later this year, could allow the Company to build a platform to commence planning
for a phase III clinical trial of efti in metastatic breast carcinoma. This will include the hypotheses for the
primary and secondary endpoints and the appropriate stratification for different patient subgroups. Immutep
will advance its discussions with the regulatory authorities accordingly.
Immutep CSO and CMO, Dr Frederic Triebel said: “The PFS results reported from the AIPAC study in a
randomised clinical setting indicate an overall trend for clinical efficacy in HR-positive metastatic breast
carcinoma, which is not a particularly immunogenic tumor and very interesting results in some meaningful
subgroups. We would like to thank the patients and their families, along with the investigators for
participating in this important study.”
Immutep CEO, Marc Voigt stated: “We are pleased to see a clinical benefit for patients receiving efti in HRpositive
metastatic breast carcinoma in multiple patient subgroups. This is just one of the four advanced solid tumor indications
targeted in our efti clinical development program. We are pleased to see an efficacy trend
and will carefully assess the data for further development of efti given our positive data in patient subgroups.
More AIPAC results should become available in the coming months, including immuno-monitoring data and
Overall Survival data.”
“Another piece of evidence for efti efficacy in cancer patients comes from the interim results we are seeing
from our ongoing phase II TACTI-002 trial of efti. In TACTI-002, 47% of first line non-small cell lung cancer
patients responding to the combination treatment of efti with pembrolizumab, an anti-PD-1 therapy. These
results are remarkable given that usually only 20% of patients respond to pembrolizumab monotherapy in
this PDL-1 all comer trial indication.”
AIPAC Principal Investigator, Hans Wildiers of University Hospitals Leuven, Leuven, Belgium, said: “I am
pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while
showing a numerically (non-significant) higher progression free survival rate compared to chemotherapy
alone. Hormone receptor positive breast tumours represent the majority of metastatic breast cancer patients
and any active well tolerated adjunct to the weekly paclitaxel standard of care regimen, is desirable. This
combination warrants further investigation in larger and more biomarker selected populations.”
Further Reporting from AIPAC
The Company expects to present these clinical results in more detail at an upcoming conference. Patients are
continuing in the follow up phase of the study enabling OS data to be collected. Immutep expects to report
OS data in late-2020.
Webcast Details
Immutep will present this AIPAC data in a global webcast, details are as follow
- Forums
- ASX - By Stock
- Ann: Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
So does the news advance the optimism or is it simply a rehash...
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.3¢ |
Change
0.018(5.93%) |
Mkt cap ! $472.0M |
Open | High | Low | Value | Volume |
31.5¢ | 35.0¢ | 31.0¢ | $1.934M | 5.946M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 415782 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 52015 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 404661 | 0.310 |
12 | 231681 | 0.305 |
25 | 314457 | 0.300 |
15 | 181709 | 0.295 |
16 | 573943 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 52015 | 10 |
0.320 | 148570 | 5 |
0.325 | 143132 | 5 |
0.330 | 176936 | 6 |
0.335 | 90166 | 3 |
Last trade - 14.57pm 01/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online